Akers Biosciences, Inc. Initial Order for Rapid Cholesterol Self-test
March 28 2017 - 7:00AM
RNS Non-Regulatory
TIDMAKR
Akers Biosciences, Inc.
28 March 2017
For release: 07.00hrs ET (12.00hrs BST) 28 March 2017
Akers Biosciences, Inc.
Akers Biosciences Begins Selling Rapid Cholesterol Test through
Distribution Agreement with First Check
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the
"Company" or "Akers Bio"), a developer of rapid health information
technologies, has received an initial order for the Company's rapid
cholesterol self-test from First Check Diagnostics, LLC ("First
Check"), the exclusive distributor for this product in the United
States, for sale under their popular "First Check" brand.
First Check products are sold through major retailers including,
CVS, Rite Aid, Target, Kmart, Meijer, Giant Eagle, Stop & Shop,
Giant and ShopKo.
Akers Bio's Tri-Cholesterol "Check" test is the only combined
rapid test which provides an estimate of a person's Total
cholesterol as well as their High Density Lipoprotein ("HDL")
cholesterol levels - their 'good cholesterol'; thereby providing an
estimate of a person's Low Density Lipoprotein ("LDL") levels -
their 'bad cholesterol'. These features are essential to accurately
differentiating between a person's 'good' and 'bad' cholesterol
thereby making it a truly effective screening test for high
cholesterol.
The Tri-Cholesterol "Check" test is disposable, uses just a
finger-stick blood sample and gives a result in only 5 minutes. The
test has FDA 510(k) clearance in the United States; as well as a CE
mark for the European Economic Area.
According to the United States Centers for Disease Control and
Prevention, 73.5 million adults (31.7%) in the United States have
high 'bad cholesterol' and less than 1 in every 3 of them has the
condition under control. Too much cholesterol puts people at risk
for heart disease and stroke, two leading causes of death in the
United States. However, with responsible actions such as
self-testing with Akers Bio's Tri-Cholesterol "Check" test, people
can take steps to manage their cholesterol levels and lower their
risk.
John J. Gormally, Chief Executive Officer of Akers Bio,
commented: "I am delighted that we will soon have this
over-the-counter health and wellness product from Akers Bio on the
shelves of major US retailers under the distinguished First Check
brand. It is a great endorsement of our rapid testing technology.
We look forward to building this revenue stream with our
distribution partner and providing people in America with a fast,
convenient and meaningful way to evaluate and manage their
cholesterol, which is a serious concern for millions of
people."
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening
and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
John J. Gormally, Chief Executive Officer
Raymond F. Akers, Jr. PhD, Vice Chairman
Tel. +1 856 848 8698
finnCap (UK Nominated Adviser and Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Vigo Communications (Global Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7830 9704
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAOKFDBCBKKQNB
(END) Dow Jones Newswires
March 28, 2017 07:00 ET (11:00 GMT)
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2023 to Apr 2024